kliniske studier er der observeret en øget risiko for dødsfald, alvorlige hjertekarhændelser og trombose m
increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater ic